Company intelligence / Profile preview

Dark Canyon Labs

Rapid City, South Dakota, United Statesdarkcanyonlabs.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 3

Overview

Completed a Phase 2 randomized, investigator-blinded, non-inferiority, multicenter study evaluating the safety and efficacy of DCL-101 compared to GoLYTELY in adult outpatients undergoing routine colonoscopy. The primary objective was to compare the safety of 3L and 4L split dose DCL-101 to split dose 4L GoLYTELY, with secondary objectives to assess tolerability and bowel cleansing efficacy[4].

Therapeutic areas: Gastroenterology
Modalities: Colonoscopy preparation solution
Industry: Biotech

Drug pipeline

3 assets

DCL-101

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Dark Canyon Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dark Canyon Labs.

Explore the full profile